TELOMIR PHARMACEUTICALS INC (TELO) Stock Analyst Earnings Estimates
NASDAQ:TELO - Nasdaq - US87975F1049 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | |||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -138.1K | -854.1K -518.46% | -3.942M -361.55% | -11.642M -195.33% | N/A 38.60% | N/A -57.52% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A 42.59% | N/A 9.68% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 | -0.08 | -0.08 16.73% | -0.07 -2.00% | -0.10 -25.00% | -0.08 | -0.09 -12.50% |
| Revenue Q2Q % growth | 510K | 1.02M | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.547M 23.53% | -2.579M 57.07% | -2.611M 10.13% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.07 | -0.10 | 0.03 | 31.37% |
| Q4 2024 Q2Q % growth | -0.10 | -0.05 | -0.05 | -92.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 20% | 0% | 22.5% |
| Revenue | N/A | N/A | N/A | N/A |